|
The poor outcome of patients with mCRPC whom were deemed ineligible for PSMA theranostics based on molecular imaging characteristics. |
|
|
No Relationships to Disclose |
|
|
|
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Merck |
Consulting or Advisory Role - Amgen |
Speakers' Bureau - Bristol-Myers Squibb; Merck |
|
|
No Relationships to Disclose |
|
|
Employment - intelerad (I) |
Stock and Other Ownership Interests - Perkin Elmer (I) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |